Adalı, ErtanYıldızhan, RecepKurdoğlu, MertihanBuğdaycı, GülerKolusarı, Ali2021-06-232021-06-2320100015-02821556-5653https://doi.org/10.1016/j.fertnstert.2009.03.037https://hdl.handle.net/20.500.12491/6692Objective: To evaluate carotid intima-media thickness and thrombin-activatable fibrinolysis inhibitor levels in young women with polycystic ovary syndrome (PCOS) and age-matched healthy controls, and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters. Design: Clinical study. Setting: University hospital. Patient(s): Fifty young women with PCOS (overweight or obese [n = 24] and nonobese [n = 26]) and 25 age-matched healthy controls. Intervention(s): History and physical examination, peripheral venous blood sampling, carotid ultrasonography. Main Outcome Measure(s): Plasma thrombin-activatable fibrinolysis inhibitor, serum FSH, LH, DHEAS, total T, E-2, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, insulin resistance defined by the homeostasis model assessment insulin resistance index, and carotid intima-media thickness. Result(s): Plasma thrombin-activatable fibrinolysis inhibitor levels in the overweight or obese PCOS group were significantly higher than those in the nonobese PCOS and control groups. Carotid intima-media thickness did not significantly differ between the groups. Obesity and insulin resistance were associated positively with plasma thrombin-activatable fibrinolysis inhibitor levels, but there was no association between carotid intima-media thickness and thrombin-activatable fibrinolysis inhibitor. Conclusion(s): Young overweight or obese women with PCOS have increased plasma thrombin-activatable fibrinolysis inhibitor levels. Impaired fibrinolysis may be responsible for the increased risk of cardiovascular diseases in women with PCOS. (Fertil Steril (R) 2010;94:666-72. (C) 2010 by American Society for Reproductive Medicine.)eninfo:eu-repo/semantics/closedAccessPolycystic Ovary SyndromeThrombin-activatable Fibrinolysis InhibitorCarotid Intima-media ThicknessCardiovascular DiseaseArticle10.1016/j.fertnstert.2009.03.037942666672193689132-s2.0-77953720441Q1WOS:000279758800038Q1